November 18, 2021

November 18, 2021

ASH 2020: Dr. Alexey Danilov on Inhibiting MCL1 to Overcome Resistance to Ibrutinib and Venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL and Other Non-Hodgkin’s Lymphoma or NHL

At the virtual American Society of Hematology Annual Meeting and Exposition or ASH 2020, Dr. Alexey Danilov of City of Hope was interviewed by CLL Society’s Steve Bloom on his important preclinical research to address one of the significant unmet needs in CLL/SLL/ patients: resistant to venetoclax and/or ibrutinib.

November 18, 2021

Getting Older and Better

since we have cancer that affects mainly older individuals, I found these two sports articles reassuring and aspirational.

November 18, 2021

ASH 2020: Dr. Jennifer Brown on Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL/SLL) Patients with Deletion 17p

At the annual meeting of the American Society of Hematology (ASH) 2020, our own Steven Bloom interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the SEQUOIA trial, which is a phase 3 trial testing

November 18, 2021

A CLL (Chronic Lymphocytic Leukemia) Patient Tells Her Story About Being Immune Compromised During the COVID-19 Pandemic and Accessing Regen-Cov (Casirivimab and Imdevimab) for Protection

For CLL/SLL patients to feel safer reentering a world where SARS-CoV-2 remains an active threat, we need more help than a vaccine that doesn’t reliably protect us. This is especially true when so many are refusing vaccination, making the prospect of herd immunity a fading fantasy.

November 18, 2021

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

This is not CLL/SLL specific but wouldn’t any immunocompromised (IC) patient feel safer if they knew there was a five-day course of an oral anti-viral medication, (PAXLOVID™ (PF-07321332; ritonavir), that when taken earlier after contracting COVID-19, gave a nine out of ten chance of preventing hospitalization and death.

November 18, 2021

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

November 18, 2021

ASH 2020: Dr. Alexey Danilov on Inhibiting MCL1 to Overcome Resistance to Ibrutinib and Venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL and Other Non-Hodgkin’s Lymphoma or NHL

Getting Older and Better

ASH 2020: Dr. Jennifer Brown on Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL/SLL) Patients with Deletion 17p

A CLL (Chronic Lymphocytic Leukemia) Patient Tells Her Story About Being Immune Compromised During the COVID-19 Pandemic and Accessing Regen-Cov (Casirivimab and Imdevimab) for Protection

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

Pfizer’s Antiviral (Paxlovid) Slashes COVID-19 Hospitalizations

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT